<DOC>
	<DOCNO>NCT00301873</DOCNO>
	<brief_summary>RATIONALE : Zoledronate may prevent bone loss patient primary malignant glioma . PURPOSE : This phase II trial study well zoledronate work prevent osteoporosis patient primary malignant glioma .</brief_summary>
	<brief_title>Zoledronate Preventing Osteoporosis Patients With Primary Malignant Glioma</brief_title>
	<detailed_description>This open-labeled trial determine incidence osteoporosis brain tumor patient effect Zometa every three month . Zometa give 4 mg intravenously 15 minute every 3 month 1 year . The patient undergo baseline bone densitometry test repeat six month one year . Information patient 's tolerability Zometa well skeletal-related complication happen collect . Data respect dose duration glucocorticoid anticonvulsant collect since therapy show directly affect bone density . Serial marker ( N-telopeptide ) bone turn collect baseline every 3 month prior infusion Zometa . Karnofsky performance status monitor function mobility . Accrual Goal 60 patient 18-month period , average 3-4 new enrollee per month . Thirty-five patient reach 6-month assessment . OBJECTIVES : - To determine bone mineral density patient baseline change 12 month receive Zometa every 3 month . - To determine incidence skeletal-related complication cohort brain tumor patient . - To determine safety tolerability Zometa brain tumor patient . - To determine effect glucocorticoids anticonvulsant bone density . Response Criteria The primary efficacy endpoint patient 's bone densitometry , change course one year Zometa therapy . The bone densitometry 6 month 12 month Zometa compare baseline . The secondary efficacy variable prevention skeletal-related event ( compression fracture , fracture require surgery ) give heterogeneity patient population qualitative variable . Date respect dose duration glucocorticoid anticonvulsant collect since therapy show directly affect bone density . Serial marker ( N-telopeptide ) bone turn collect . Outcome assessment The patient 's bone densitometry determine Dexa-scan baseline , six month Zometa one year Zometa . The bone density ( Dexa- scan ) review outside radiologist Duke radiology conjunction primary investigator . A decrease &gt; -0.5 T-score cod treatment failure patient discontinue study referred Endocrinology Orthopedic Surgery best clinical management . In addition , skeletal-related event ( fracture ) cod treatment failure . The patient population heterogeneous term functional capacity , exercise capacity , anticonvulsant glucocorticoid do</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>1 . Patients must histologically confirm diagnosis primary brain tumor . 2 . Patients must Depakote ( Valproic Acid ) one follow enzyme induce anticonvulsant ( EIAC ) therapy . Phenobarbital , Dilantin , Trileptal , Tegretol and/or physiologic replacement steroid therapy ( Dexamethasone &gt; 0.75 mg/d , prednisone &gt; 5 mg/d hydrocortisone &gt; 20 mg/d ) . 3 . Age &gt; 18 year . 4 . Karnofsky performance score &gt; 60 % 5 . Adequate renal liver function demonstrate laboratory value perform within 14 day , inclusive , prior administration Zometa , except creatinine , within 72 h Zometa administration : Serum creatinine &lt; 2.0 mg/dl calculate creatinine clearance &gt; 60 mL/min Total serum bilirubin &lt; 1.5 time upper limit laboratory normal Serum glutamocoxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &lt; 2.5 time upper limit laboratory normal Alkaline phosphatase &lt; 2 time upper limit laboratory normal 6 . Patients must recover effect major surgery . 7 . Patients must life expectancy great 12 week . 8 . Patients legal guardian must give write , informed consent . 1 . Patients poor medical risk nonmalignant systemic disease well acute infection treat intravenous antibiotic . 2 . Previous concurrent malignancy sit exception surgically cure carcinoma insitu cervix basal squamous cell carcinoma skin . 3 . Known HIV positivity AIDSrelated illness . 4 . Pregnant nursing woman . 5 . Women childbearing potential use effective method contraception . Women childbearing potential must negative serum pregnancy test 72hours prior administration study practice medically approve contraceptive precaution . 6 . Men advise use effective method contraception . 7 . Patients previously diagnose osteoporosis require oral bisphosphonates . 8 . Known hypersensitivity ZometaÂ® ( zoledronic acid ) bisphosphonates 9 . Current active dental problem include infection teeth jawbone osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . 10 . Recent ( within 6 week ) plan dental jaw surgery ( e.g.. extraction , implant ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>